Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.83 |
| ▸ | THRB | P10828 | 8/20 | 0.83 |
| ▸ | BLM | P54132 | 7/20 | 0.83 |
| ▸ | RECQL | P46063 | 6/20 | 0.83 |
| ▸ | TOP2A | P11388 | 5/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.83 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.83 |
| ▸ | MAPT | P10636 | 4/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.83 |
| ▸ | HTT | P42858 | 4/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.83 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.83 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.83 |
| ▸ | FYN | P06241 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1771543 | 0.99 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL27900762 | 0.99 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL147968 | 0.97 | MEN1 (0.79) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL22409662 | 0.97 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL27834123 | 0.96 | MEN1 (0.91) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL4586684 | 0.96 | MEN1 (0.81) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL29048581 | 0.96 | MEN1 (0.79) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL23117782 | 0.95 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL16622415 | 0.95 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL20307182 | 0.95 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3287 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227018-A1 | FUSION PROTEIN TARGETING CELL MEMBRANE RECEPTOR PROTEINS AND USE THEREOF | 羿尊生物医药（浙江）有限公司 | 2023-11-30 | — | — | WO | claimed |
| WO-2023222019-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | 成都百利多特生物药业有限责任公司 | 2023-11-23 | — | — | WO | claimed |
| WO-2023141560-A2 | ALKALINE PHOSPHATASE FOR USE IN ONCOLOGY | SYNTHETIC BIOLOGICS, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| US-20220298252-A1 | METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES | PELICAN THERAPEUTICS, INC. | 2022-09-22 | — | — | US | claimed |
| EP-4021494-A1 | METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES | Pelican Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220185863-A1 | COMBINATION THERAPIES | SHATTUCK LABS, INC. | 2022-06-16 | — | — | US | claimed |
| CN-114502195-A | Methods of treating cancer using TNFRSF25 antibodies | 派立卡恩治疗公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2022081521-A1 | INOSITOL-BISPYROPHOSPHATE-DERIVED COMPOUNDS AND USES THEREOF | NICOLAU YVES CLAUDE (US) | 2022-04-21 | — | — | WO | claimed |
| EP-3930851-A1 | COMBINATION THERAPIES | Shattuck Labs, Inc. (US) | 2022-01-05 | — | — | EP | claimed |
| CN-113747947-A | Combination therapy | 沙塔克实验室有限公司 | 2021-12-03 | — | — | CN | claimed |
| EP-2508184-A1 | Pyridopyrazine derivatives and their use | Æterna Zentaris GmbH (DE) | 2012-10-10 | — | — | EP | claimed |
| JP-4701159-B2 | — | — | 2011-06-15 | — | — | JP | claimed |
| EP-1962854-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | AEterna Zentaris GmbH (DE) | 2008-09-03 | — | — | EP | claimed |
| EP-1957487-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | AEterna Zentaris GmbH (DE) | 2008-08-20 | — | — | EP | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| WO-2007079999-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | ÆTERNA ZENTARIS GMBH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1790342-A1 | Pyridopyrazine derivatives and their use as signal transduction modulators | Zentaris GmbH (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2007054556-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ÆTERNA ZENTARIS GMBH (DE) | 2007-05-18 | — | — | WO | claimed |
| EP-1785423-A1 | Pyridopyrazine derivatives and their use as kinase modulators | Zentaris GmbH (DE) | 2007-05-16 | — | — | EP | claimed |